ASX Filings

Opthea Finalizes Study Designs and Start-up Activities for Phase 3 Pivotal Clinical Trials of OPT-302 in Wet AMD

February 24, 2021

Additional Formats

PDF Version

Opthea Half Year Report and Accounts

February 22, 2021

Change in substantial holding

February 19, 2021

Opthea to Present at the 10th Annual SVB Leerink Global Healthcare Conference

February 17, 2021

Additional Formats

PDF Version

Change in substantial holding

February 16, 2021

Change in substantial holding

February 1, 2021

Becoming a substantial holder

January 22, 2021

Results of Meeting

January 19, 2021

Ceasing to be a substantial holder

January 15, 2021

Becoming a substantial holder

December 17, 2020